tbuckley/cabot-search huggingface dataset:
Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study
Authors: David Belada, Katerina Kopeckova, Juan Miguel Bergua Burgues, Don Stevens, Marc André, Ernesto Perez Persona, Petra Pichler, Philipp B. Staber, Marek Trneny, Johannes Duell, Maeve Waldron-Lynch, Steve Wagner, Amitava Mukhopadhyay, Maren Dirnberger-Hertweck, John M. Burke, Grzegorz S. Nowakowski
Journal: Blood (2023)

Anti-CD19 immunotherapy tafasitamab is used in combination with lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible for autologous stem cell transplant. Open-label, phase 1b, First-MIND study assessed safety and preliminary efficacy of tafasitamab + R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) ± lenalidomide as first-line therapy in patients with DLBCL. From December 2019 to August 2020, 83 adults with untreated DLBCL (International Prognostic Index 2-5) were screened and 66 were randomly assigned (33 per arm) to R-CHOP-tafasitamab (arm T) or R-CHOP-tafasitamab-lenalidomide (arm T/L) for 6 cycles. Primary end point was safety; secondary end points included end-of-treatment (EoT) overall response rate (ORR) and complete response (CR) rate. All patients had ≥1 treatment-emergent adverse event, mostly grade 1 or 2. Grade ≥3 neutropenia and thrombocytopenia occurred, respectively, in 57.6% and 12.1% (arm T) and 84.8% and 36.4% (arm T/L) of patients. Nonhematologic toxicities occurred at similar rates among arms. R-CHOP mean relative dose intensity was ≥89% in both arms. EoT ORR was 75.8% (CR 72.7%) in arm T and 81.8% (CR 66.7%) in arm T/L; best ORR across visits was 90.0% and 93.9%. Eighteen-month duration of response and of CR rates were 72.7% and 74.5% (arm T) and 78.7% and 86.5% (arm T/L); 24-month progression-free and overall survival rates were 72.7% and 90.3% (arm T) and 76.8% and 93.8% (arm T/L). Manageable safety and promising signals of efficacy were observed in both arms. Potential benefit of adding tafasitamab + lenalidomide to R-CHOP is being investigated in phase 3 frontMIND (NCT04824092). This study is registered at www.clinicaltrials.gov as #NCT04134936.
Unamplified and Label‐Free Detection of HPV16 DNA Using CRISPR‐Cas12a‐Functionalized Solution‐Gated Graphene Transistors
Authors: Huibin Zhang, Minghua Deng, Ziqin Li, Zhanpeng Ren, Lei Zhang, Ming Wang, Shupeng Jiang, Li Yu, Xianbao Wang, Jinhua Li
Journal: Advanced Healthcare Materials (2023)

The persistent infection of high-risk-human papillomavirus type 16 (HPV16) is considered an essential element for suffering cervical cancer. Despite polymerase chain reaction, loop-mediated amplification, and microfluidic chips are used to detect the HPV16, these methods still exist some drawbacks including time-consuming and false positive results. The CRISPR-Cas system is widely used in the region of biological detection due to its precise targeted recognition capability. In this contribution, the novel solution-gated graphene transistor sensor is designed to realize the unamplified and label-free detection of HPV16 DNA. Using the precise recognition of the CRISPR-Cas12a system and the gate functionalization, HPV16 DNA can be precisely identified without need the amplification and labeling. The limit of detection of the sensor can be up to 8.3 × 10-18 m and the detection can be within 20 min. Additionally, the heat-Inactivated clinical samples can be clearly distinguished by the sensor the diagnosis results have a high degree of agreement with q-PCR detection.
More Than 80% of the World’s Morphine Goes to North America, Europe
Authors: Emily Harris
Journal: JAMA (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Investigation of Active Ingredients Within Internet-Delivered Cognitive Behavioral Therapy for Depression
Authors: Edward Watkins, Alexandra Newbold, Michelle Tester-Jones, Linda M. Collins, Mohammod Mostazir
Journal: JAMA Psychiatry (2023)

There is limited understanding of how complex evidence-based psychological interventions such as cognitive behavioral therapy (CBT) for depression work. Identifying active ingredients may help to make therapy more potent, brief, and scalable.
Characterization of Brain Volume Changes in Aging Individuals With Normal Cognition Using Serial Magnetic Resonance Imaging
Authors: Shohei Fujita, Susumu Mori, Kengo Onda, Shouhei Hanaoka, Yukihiro Nomura, Takahiro Nakao, Takeharu Yoshikawa, Hidemasa Takao, Naoto Hayashi, Osamu Abe
Journal: JAMA Network Open (2023)

Characterizing longitudinal patterns of regional brain volume changes in a population with normal cognition at the individual level could improve understanding of the brain aging process and may aid in the prevention of age-related neurodegenerative diseases.To investigate age-related trajectories of the volumes and volume change rates of brain structures in participants without dementia.This cohort study was conducted from November 1, 2006, to April 30, 2021, at a single academic health-checkup center among 653 individuals who participated in a health screening program with more than 10 years of serial visits.Serial magnetic resonance imaging, Mini-Mental State Examination, health checkup.Volumes and volume change rates across brain tissue types and regions.The study sample included 653 healthy control individuals (mean [SD] age at baseline, 55.1 [9.3] years; median age, 55 years [IQR, 47-62 years]; 447 men [69%]), who were followed up annually for up to 15 years (mean [SD], 11.5 [1.8] years; mean [SD] number of scans, 12.1 [1.9]; total visits, 7915). Each brain structure showed characteristic age-dependent volume and atrophy change rates. In particular, the cortical gray matter showed a consistent pattern of volume loss in each brain lobe with aging. The white matter showed an age-related decrease in volume and an accelerated atrophy rate (regression coefficient, -0.016 [95% CI, -0.012 to -0.011]; P < .001). An accelerated age-related volume increase in the cerebrospinal fluid-filled spaces, particularly in the inferior lateral ventricle and the Sylvian fissure, was also observed (ventricle regression coefficient, 0.042 [95% CI, 0.037-0.047]; P < .001; sulcus regression coefficient, 0.021 [95% CI, 0.018-0.023]; P < .001). The temporal lobe atrophy rate accelerated from approximately 70 years of age, preceded by acceleration of atrophy in the hippocampus and amygdala.In this cohort study of adults without dementia, age-dependent brain structure volumes and volume change rates in various brain structures were characterized using serial magnetic resonance imaging scans. These findings clarified the normal distributions in the aging brain, which are essential for understanding the process of age-related neurodegenerative diseases.
Estimated Prevalence of Perinatal Depression in Low- and Middle-Income Countries Considering Uncertainty of Test Properties—Reply
Authors: Alexandra Roddy Mitchell, Stephen Tong, Roxanne Hastie
Journal: JAMA Psychiatry (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Daily Dose of Aspirin Linked With Anemia in Older People
Authors: Emily Harris
Journal: JAMA (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Moderate‐Affinity Affibodies Modulate the Delivery and Bioactivity of Bone Morphogenetic Protein‐2
Authors: Jonathan Dorogin, Henry B. Hochstatter, Samantha O. Shepherd, Justin E. Svendsen, Morrhyssey A. Benz, Andrew C. Powers, Karly M. Fear, Jakob M. Townsend, James S. Prell, Parisa Hosseinzadeh, Marian H. Hettiaratchi
Journal: Advanced Healthcare Materials (2023)

Abstract Uncontrolled bone morphogenetic protein‐2 (BMP‐2) release can lead to off‐target bone growth and other adverse events. To tackle this challenge, yeast surface display is used to identify unique BMP‐2‐specific protein binders known as affibodies that bind to BMP‐2 with different affinities. Biolayer interferometry reveals an equilibrium dissociation constant of 10.7 n m for the interaction between BMP‐2 and high‐affinity affibody and 34.8 n m for the interaction between BMP‐2 and the low‐affinity affibody. The low‐affinity affibody‐BMP‐2 interaction also exhibits an off‐rate constant that is an order of magnitude higher. Computational modeling of affibody‐BMP‐2 binding predicts that the high‐ and low‐affinity affibodies bind to two distinct sites on BMP‐2 that function as different cell‐receptor binding sites. BMP‐2 binding to affibodies reduces expression of the osteogenic marker alkaline phosphatase (ALP) in C2C12 myoblasts. Affibody‐conjugated polyethylene glycol‐maleimide hydrogels increase uptake of BMP‐2 compared to affibody‐free hydrogels, and high‐affinity hydrogels exhibit lower BMP‐2 release into serum compared to low‐affinity hydrogels and affibody‐free hydrogels over four weeks. Loading BMP‐2 into affibody‐conjugated hydrogels prolongs ALP activity of C2C12 myoblasts compared to soluble BMP‐2. This work demonstrates that affibodies with different affinities can modulate BMP‐2 delivery and activity, creating a promising approach for controlling BMP‐2 delivery in clinical applications.
Potential Limitations for Assessing the Association of Whole Blood With Survival in Patients With Severe Hemorrhage—Reply
Authors: Crisanto M. Torres, Elliott R. Haut, Joseph V. Sakran
Journal: JAMA Surgery (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Meta-Analysis: Social Isolation, Loneliness Tied to Higher Mortality
Authors: Emily Harris
Journal: JAMA (2023)

Social isolation and loneliness were associated with a 32% and 14% higher risk, respectively, of all-cause mortality, as well as an increased risk of cancer mortality, according to a meta-analysis of 90 prospective cohort studies that included more than 2 million adults aged 18 years or older.
Time to clinical benefit of eplerenone among patients with heart failure and reduced ejection fraction: A subgroups analysis from the <scp>EMPHASIS‐HF</scp> trial
Authors: Luca Monzo, Nicolas Girerd, Kevin Duarte, João Pedro Ferreira, John J.V. McMurray, Dirk J. van Veldhuisen, Karl Swedberg, Stuart J. Pocock, Bertram Pitt, Faiez Zannad
Journal: European Journal of Heart Failure (2023)
Comments on the myPACE Randomized Clinical Trial—Reply
Authors: Margaret Infeld, Daniel L. Lustgarten, Markus Meyer
Journal: JAMA Cardiology (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Patients With COVID-19 and Fungal Infections Had High Mortality Rates
Authors: Emily Harris
Journal: JAMA (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Sarcomatoid transformation of a basal cell carcinoma following treatment with hedgehog inhibitors
Authors: Cristina Barrabés-Torrella, Jorge Arandes-Marcocci, Lucia Armillas-Lliteras, Rodolfo A Posada-Caez, Inessa Koptseva, Caterina Fumagalli, David Piñol-Ballús, Montse Salleras-Redonnet
Journal: British Journal of Dermatology (2023)

Vismodegib and sonidegib are sonic hedgehog inhibitors (SHHIs) available for the treatment of advanced basal cell carcinoma (BCC). Cases of sarcomatoid differentiation during treatment of BCC with SHHIs have not been previously reported. We present a unique case of a locally advanced BCC that underwent sarcomatoid transformation, manifesting as a large mass complicated by local invasion and lung metastases, following treatment with sonidegib.
Examination of the Accuracy of Existing Overdose Surveillance Systems
Authors: Jennifer Griffith, Laura C. Chambers, Benjamin D. Hallowell, Ashley Gaipo, Craig Mailloux, Janette Baird, Francesca L. Beaudoin, Elizabeth A. Samuels
Journal: JAMA Network Open (2023)

Importance Health departments have used a variety of methods for overdose surveillance, and the Centers for Disease Control and Prevention (CDC) is implementing a standardized case definition to improve overdose surveillance nationally. The comparative accuracy of the CDC opioid overdose case definition vs existing state opioid overdose surveillance systems is unknown. Objective To evaluate the accuracy of the CDC opioid overdose case definition and existing Rhode Island Department of Health (RIDOH) state opioid overdose surveillance system. Design, Setting, and Participants This cross-sectional study of ED opioid overdose visits was conducted at 2 EDs in Providence, Rhode Island, at the state’s largest health system from January to May 2021. Electronic health records (EHRs) were reviewed for opioid overdoses identified by the CDC case definition and opioid overdoses reported to the RIDOH state surveillance system. Included patients were those at study EDs whose visit met the CDC case definition, was reported to the state surveillance system, or both. True overdose cases were confirmed by EHR review using a standard case definition; 61 of 460 EHRs (13.3%) were double reviewed to estimate classification accuracy. Data were analyzed from January through May 2021. Main Outcome and Measure Accurate identification of an opioid overdose was assessed by estimating the positive predictive value of the CDC case definition and state surveillance system using results from the EHR review. Results Among 460 ED visits that met the CDC opioid overdose case definition, were reported to the RIDOH opioid overdose surveillance system, or both (mean [SD] age, 39.7 [13.5] years; 313 males [68.0%]; 61 Black [13.3%], 308 White [67.0%], and 91 other race [19.8%]; and 97 Hispanic or Latinx [21.1%] among each patient visit), 359 visits (78.0%) were true opioid overdoses. For these visits, the CDC case definition and RIDOH surveillance system agreed that 169 visits (36.7%) were opioid overdoses. Of 318 visits meeting the CDC opioid overdose case definition, 289 visits (90.8%; 95% CI, 87.2%-93.8%) were true opioid overdoses. Of 311 visits reported to the RIDOH surveillance system, 235 visits (75.6%; 95% CI, 70.4%-80.2%) were true opioid overdoses. Conclusions and Relevance This cross-sectional study found that the CDC opioid overdose case definition more often identified true opioid overdoses compared with the Rhode Island overdose surveillance system. This finding suggests that using the CDC case definition for opioid overdose surveillance may be associated with improved data efficiency and uniformity.
Trial Participation and Outcomes Among English-Speaking and Spanish-Speaking Patients With Appendicitis Randomized to Antibiotics
Authors: Elina Serrano, Emily C. Voldal, David Machado-Aranda, Daniel A. DeUgarte, Lillian Kao, Thurston Drake, Robert Winchell, Joseph Cuschieri, Anusha Krishnadasan, David A. Talan, Nicole Siparsky, Patricia Ayoung-Chee, Wesley H. Self, Patrick McGonagill, Katherine A. Mandell, Mike K. Liang, Shan-Jahan Dodwad, Callie M. Thompson, Reynaldo M. Padilla, Ross Fleischman, Thea P. Price, Alan Jones, Karla Bernardi, Luis Garcia, Heather L. Evans, Sabrina E. Sanchez, Stephen Odom, Bryan A. Comstock, Patrick J. Heagerty, Sarah O. Lawrence, Sarah E. Monsell, Erin E.C. Fannon, Larry G. Kessler, David R. Flum, Giana H. Davidson, Mohamad Abouzeid, Hasan B. Alam, Hikmatullah Arif, Karla Ballman, Robert Bennion, Debra Burris, Damien Carter, Formosa Chen, Bruce Chung, Sunday Clark, Randall Cooper, Joseph Cuschieri, Kimberly Deeney, Naila Dhanani, Thomas Diflo, Cathy Fairfield, Farhood Farjah, Lisa Ferrigno, Careen Foster, Terilee Gerry, Melinda Gibbons, Mary Guiden, Nathan Haas, Lillian Adrianna Hayes, Alyssa Hayward, Laura Hennessey, Miriam Hernandez, Karen F. Horvath, Erin C. Howell, Cindy Hsu, Jeffrey Johnson, Billie Johnsson, Dennis Kim, Daniel Kim, Tien C. Ko, Danielle C. Lavallee, Debbie Lew, Joseph Mack, David MacKenzie, Jason Maggi, Stephanie Marquez, Ryan Martinez, Karen McGrane, Marcovalerio Melis, Karen Miller, Debbie Mireles, Gregory J. Moran, Dayna Morgan, Arden Morris, Kelly M. Moser, Lauren Mount, Kathleen O'Connor, Oscar Olavarria, Norman Olbrich, Scott Osborn, Olga Owens, Pauline Park, Zoe Parr, Charles S. Parsons, Kavitha Pathmarajah, Deepti Patki, Joe H. Patton, Rebekah K. Peacock, Kristyn Pierce, Kelsey Pullar, Brant Putnam, Amy Rushing, Amber Sabbatini, Darin Saltzman, Matthew Salzberg, Shaina Schaetzel, Paul J Schmidt, Paresh Shah, Nathan I. Shapiro, Prashant Sinha, Dionne Skeete, Elliott Skopin, Vance Sohn, Lara H. Spence, Steven Steinberg, Aleksandr Tichter, John Tschirhart, Brandon Tudor, Lisandra Uribe, Heather VanDusen, Julie Wallick, Meridith Weiss, Sean Wells, Abigail Wiebusch, Estell J. Williams, Robert J. Winchell, Jon Wisler, Bruce Wolfe, Erika Wolff, Donald M. Yealy, Julianna Yu
Journal: JAMA Surgery (2023)

Spanish-speaking participants are underrepresented in clinical trials, limiting study generalizability and contributing to ongoing health inequity. The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) trial intentionally included Spanish-speaking participants.